Drug Delivery and Nanotechnology Module

药物输送和纳米技术模块

基本信息

批准号：
10700932
负责人：
Kannan Rangaramanujam
金额：
$ 7.78万
依托单位：
JOHNS HOPKINS UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
1997
资助国家：
美国
起止时间：
1997-07-01 至 2025-08-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10700932
关键词：
Animal Model Animals Basic Science Biological Cell Culture Techniques Cells Clinical Research Collaborations Communities Core Grant Cultured Cells Development Devices Doctor of Philosophy Dose Dose Limiting Drug Delivery Systems Eye Eye diseases Faculty Gene Delivery Gene Expression Genes Genetic Engineering Glaucoma Grant Human In Vitro Legal patent Licensing Nanotechnology Nucleic Acids Optic Nerve Injuries Outcome Pathogenesis Pathway interactions Pharmaceutical Preparations Phenotype Proteins Publications Research Research Personnel Resources Retinopathy of Prematurity Services Site System Technology Therapeutic Therapeutic Effect Tissues Toxic effect Transfection United States National Institutes of Health Vision research Work clinical translation drug discovery eye dryness imaging approach in vivo interest nanomedicine nanoparticle nanoscale novel imaging technology novel therapeutic intervention novel therapeutics particle pre-clinical small molecule targeted delivery technology platform therapeutic target tissue culture tool vector vision science

项目摘要

PROJECT SUMMARY – NANOTECHNOLOGY The Drug Delivery and Nanotechnology (DD&N) module is an enabling technology resource available to faculty of the Wilmer Eye Institute, by enabling sustained and targeted delivery of drugs administered intravitreally, subconjunctivally, or systemically, and in developing novel imaging technologies. During the current period, the collaborations have resulted many NIH grants, publications, many patents licensed, and significant translational efforts, with multiple therapeutic approaches developed by the Wilmer P30 team undergoing clinical translation. DD&N takes advantage of the expertise, technologies, and resources of the Wilmer Eye Institute’s Center for Nanomedicine (CNM). The Center for Nanomedicine at Wilmer serves as an anchor for the DD&N module, and has grown to seven faculty, collaborating with more than 15 faculty in Wilmer and more than 100 faculty across Johns Hopkins. Demand by Wilmer investigators (both established and early investigators) for the development and characterization of drug delivery systems for small molecules, proteins, and nucleic acids have grown well beyond the available budgetary restrictions of the CNM, with the DD&N becoming an integral part of the P30 effort. Our collaborative efforts have led to significant progress in novel therapeutic approaches for the treatment of glaucoma, optic nerve injury, retinopathy of prematurity, and dry eye. The DD&N module will continue to thrive and enable significant discoveries by the P30 collaborators.

项目摘要 - 纳米技术药物输送和纳米技术（DD＆N）模块是可用的技术资源通过实现毒品的持续和有针对性的毒品，向威尔默眼科研究所的教师在开发新型成像时进行玻璃体内，副结合或系统地施用技术。出版物，许多专利获得许可和重大翻译工作，并具有多种治疗性 Wilmer P30团队正在开发临床翻译。威尔默眼协会中心的专业知识，技术和资源的优势纳米医学（CNM）。模块，已经成长为七个教职员工，与威尔默的15多名教师合作等等约翰·霍普金斯（Johns Hopkins）的100名教职员工。研究人员）针对小分子的药物输送系统的开发和表征，蛋白质和核酸已远远超出了CNM的可用预算限制，随着DD＆N成为P30的组成部分。新型治疗方法治疗Glavaucoma，视神经损伤，预防性的视网膜病和干眼。 P30合作者的重大发现。